Loading clinical trials...
Loading clinical trials...
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Conditions
Interventions
deucrictibant
deucrictibant
Locations
63
United States
Study site
Birmingham, Alabama, United States
Study site
Scottsdale, Arizona, United States
Study site
Little Rock, Arkansas, United States
Study site
San Diego, California, United States
Study site
Santa Monica, California, United States
Study site
Walnut Creek, California, United States
Start Date
December 28, 2022
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2027
Last Updated
March 16, 2026
NCT06960213
NCT07001280
NCT07298447
NCT06842823
NCT06573723
NCT05397431
Lead Sponsor
Pharvaris Netherlands B.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions